|
Corning Life Sciences
rt-quic mastermix Rt Quic Mastermix, supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/rt-quic+assays/rt+quic+mastermix/pm37964018-282-4-16 Average 90 stars, based on 1 article reviews
rt-quic mastermix - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
National Reference Center for Legionella
rt-quic protocol Rt Quic Protocol, supplied by National Reference Center for Legionella, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/rt-quic+assays/rt+quic+protocol/pm39607039-385-43-9 Average 90 stars, based on 1 article reviews
rt-quic protocol - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Amprion Inc
pmca (rt-quic) ![]() Pmca (Rt Quic), supplied by Amprion Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/rt-quic+assays/rt+quic/pmc07066875-476-16-24 Average 90 stars, based on 1 article reviews
pmca (rt-quic) - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
rocky mountain labs
rt-quic ![]() Rt Quic, supplied by rocky mountain labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/rt-quic+assays/rt+quic/pmc07664259-47-47-59 Average 90 stars, based on 1 article reviews
rt-quic - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
HEIDENHAIN Ltd
rt-quic assay ![]() Rt Quic Assay, supplied by HEIDENHAIN Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/rt-quic+assays/rt+quic+assay/pmc09867951-18-16-7 Average 90 stars, based on 1 article reviews
rt-quic assay - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
OPS DIAGNOSTICS
α- syn rt- quic reaction mixture ![]() α Syn Rt Quic Reaction Mixture, supplied by OPS DIAGNOSTICS, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/rt-quic+assays/%CE%B1++syn+rt++quic+reaction+mixture/pm39259788-430-13-33 Average 90 stars, based on 1 article reviews
α- syn rt- quic reaction mixture - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Institute for Clinical Pharmacodynamics
α-synuclein real-time quaking induced conversion (α-syn rt-quic) assay ![]() α Synuclein Real Time Quaking Induced Conversion (α Syn Rt Quic) Assay, supplied by Institute for Clinical Pharmacodynamics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/rt-quic+assays/%CE%B1+synuclein+real+time+quaking+induced+conversion++%CE%B1+syn+rt+quic++assay/10__1080_slash_19336896__2022__2091286-3116-50-39 Average 90 stars, based on 1 article reviews
α-synuclein real-time quaking induced conversion (α-syn rt-quic) assay - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
rPeptide
rt-quic cleveland asyn rec wt ![]() Rt Quic Cleveland Asyn Rec Wt, supplied by rPeptide, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/rt-quic+assays/rt+quic+cleveland+asyn+rec+wt/pmc10457253-50-6-11 Average 90 stars, based on 1 article reviews
rt-quic cleveland asyn rec wt - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Fisher Scientific
rt-quic sample buffer 0.1% sds ![]() Rt Quic Sample Buffer 0.1% Sds, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/rt-quic+assays/rt+quic+sample+buffer+0+1++sds/pm36383520-91-4-9 Average 90 stars, based on 1 article reviews
rt-quic sample buffer 0.1% sds - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Proteostasis Therapeutics
rt-quic ![]() Rt Quic, supplied by Proteostasis Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/rt-quic+assays/rt+quic/pmc11477186-19-41-100 Average 90 stars, based on 1 article reviews
rt-quic - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Biofluids Inc
αsyn saa real-time quaking-induced conversion (rt-quic) ![]() αsyn Saa Real Time Quaking Induced Conversion (Rt Quic), supplied by Biofluids Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/rt-quic+assays/%CE%B1syn+saa+real+time+quaking+induced+conversion++rt+quic+/pmc11920727-16-108-93 Average 90 stars, based on 1 article reviews
αsyn saa real-time quaking-induced conversion (rt-quic) - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
OPS DIAGNOSTICS
asyn rt-quic reaction mixture ![]() Asyn Rt Quic Reaction Mixture, supplied by OPS DIAGNOSTICS, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/rt-quic+assays/asyn+rt+quic+reaction+mixture/pmc09922999-65-15-32 Average 90 stars, based on 1 article reviews
asyn rt-quic reaction mixture - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Nature
Article Title: Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy
doi: 10.1038/s41586-020-1984-7
Figure Lengend Snippet: a, b, Samples of CSF (40 μl) from patients with PD (PD), patients with MSA or healthy control individuals (HC) were subjected to α-syn-PMCA and the extent of aggregation was monitored by ThT fluorescence. a, Maximum fluorescence values (measured at plateau of aggregation) for PD (n = 94; red), MSA (n = 75; blue) and healthy controls (n = 56; black). Each dot represents an individual biological sample measured in duplicate and data are mean ± s.e.m. b, Representative aggregation curves of α-syn in the presence of CSF from patients with PD (n = 47), patients with MSA (n = 30) and healthy controls (n = 42). Data are mean ± s.e.m. of all patients analysed in each group. c, d, Frozen brain samples from patients with pathologically confirmed PD or MSA, or from healthy controls, were homogenized at 10% w/v. A 0.001% dilution of brain homogenate was used for the α-syn-PMCA reaction. c, Maximum fluorescence values for PD (n = 3), MSA (n = 3) and healthy controls (n = 3). Each dot represents an individual biological sample measured in duplicate and data are mean ± s.e.m. of three patients in each group. ****P < 0.0001 by one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison test (a, c). d, Aggregation profiles of α-syn in the presence of samples from the brain of patients with PD (n = 3), patients with MSA (n = 3) and healthy controls (n = 3). Data are mean ± s.e.m. of three patients in each group. e–h, Differential binding of two amyloid-conformation-specific dyes (HS-199 and HS-169) to α-syn aggregates obtained after two rounds of α-syn-PMCA in samples from the CSF (e, g; n = 43) or the brain (f, h; n = 3) of different patients with PD or MSA. Excitation was at 540 nm and the emission spectrum was recorded between 580 and 800 nm. The chemical structures of HS-199 and HS-169 are also shown. Each experiment was performed in duplicate and data are mean ± s.e.m. (for many points the error bars are smaller than the symbols).
Article Snippet: The University of Texas Health Science Center at Houston owns some patent applications related to the
Techniques: Control, Fluorescence, Comparison, Binding Assay
Journal: Nature
Article Title: Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy
doi: 10.1038/s41586-020-1984-7
Figure Lengend Snippet: a–c, α-Syn-PMCA products starting from samples of CSF from patients with MSA or patients with PD were incubated without (−) or in the presence of increasing concentrations of proteinase K (PK; 0.001, 0.01, 0.1 and 1 mg ml−1) at 37 °C for 1 h. Samples were subjected to western blotting using three different antibodies against α-syn: N-19 (Santa Cruz), which recognizes the N-terminal region (residues 1–50) of α-syn (a); anti-α-syn clone 42 (BD Biosciences), which is raised against the middle region of α-syn (residues 15–123) (b); and 211 (Santa Cruz), which is reactive against the C-terminal region of α-syn (residues 121–125) (c). Similar results were obtained for three other patients analysed per disease (Extended Data Fig. 4). d, Profiles of digested fragments from five patients in each group, developed with the BD clone 42 anti-α-syn antibody. The results for all of the PD (n = 43) and MSA (n = 43) samples analysed are shown in Extended Data Fig. 5. For the experiments in a–d, we used the aggregates from the second round of amplification. e, Profile of proteinase- K-resistant fragments after serial rounds of α-syn-PMCA. The first round corresponds to direct amplification from the CSF. For the second round of amplification, aggregates produced in the first round were diluted 100-fold into fresh α-syn monomer substrate and a new round of α-syn-PMCA was performed. The assay was then repeated for the third and fourth rounds using amplified α-syn aggregates (1%) from the previous round. As before, amplified aggregates were treated with proteinase K (1 mg ml−1) and blots were developed with the BD clone 42 anti-α-syn antibody. f, Proteinase K resistance profiles of aggregates amplified from the brain of patients with neuropathologically confirmed PD (n = 3) or MSA (n = 3). Molecular weight markers (kDa) are indicated on the left of each blot.
Article Snippet: The University of Texas Health Science Center at Houston owns some patent applications related to the
Techniques: Incubation, Western Blot, Amplification, Produced, Molecular Weight
Journal: Nature
Article Title: Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy
doi: 10.1038/s41586-020-1984-7
Figure Lengend Snippet: a, Circular dichroism spectra of α-syn aggregates from the CSF of patients with PD (red) or patients with MSA (blue), amplified by two rounds of α-syn-PMCA. Spectra were recorded from 35 μM suspensions of α-syn aggregates, as described in Methods. Measurements were taken for all of the PD (n = 43) and MSA (n = 43) samples analysed and data (molar ellipticity) are mean ± s.e.m. b, A similar experiment was performed for α-syn aggregates that were amplified from the brain of patients with PD (n = 3) or patients with MSA (n = 3). c, FTIR spectra of α-syn aggregates that were obtained after two rounds of seeding and amplification of samples of CSF from patients with PD (n = 10) or patients with MSA (n = 10). The solution of aggregated proteins (5 μl; 5 mg ml−1) was analysed with an FTIR-4100 spectrometer (JASCO). d, Cryo-ET was performed to evaluate structural differences between fibrils from patients with PD and fibrils from patients with MSA. Central slices of representative subtomograms of PD-associated fibrils and MSA-associated fibrils are shown. The negative-stained fibrils were imaged with a 300-kV electron microscope (Methods). Yellow arrows indicate twists in the filaments. Scale bar, 20 nm. e, Three-dimensional density maps segmented from the original tomograms. Boxed densities are magnified views. f, Three-dimensional helical models were built that overlapped with the corresponding densities of PD- and MSA-associated fibrils, including a magnification of the central region. g, Helical models showing the periodicity of twisting of PD- or MSA-associated fibrils. Black arrows indicate the twist in the 3D model of the filament. h, Quantification of the periodic spacing (in nm) in many different fibrils derived from samples from patients with PD (n = 3) or patients with MSA (n = 3) samples. Each dot corresponds to a different fibril and data are mean ± s.e.m. *P < 0.05 by one-way ANOVA followed by Tukey’s multiple comparison test.
Article Snippet: The University of Texas Health Science Center at Houston owns some patent applications related to the
Techniques: Circular Dichroism, Amplification, Tomography, Staining, Microscopy, Derivative Assay, Comparison
Journal: Neurotherapeutics
Article Title: Fluid and Biopsy Based Biomarkers in Parkinson’s Disease
doi: 10.1007/s13311-023-01379-z
Figure Lengend Snippet: Changes in biomarkers compared to healthy control populations. As PD progresses, there is heterogeneity in the change in biomarker profiles such that some patients may increase or decrease in certain biomarkers, but others may remain stable (↑ = or ↓ =). There are competing articles about the changes seen in oligomeric aSyn over time (↓↑)
Article Snippet: Kuzkina et al. [ ] ,
Techniques: Control, Biomarker Discovery, Clinical Proteomics
Journal: Neurotherapeutics
Article Title: Fluid and Biopsy Based Biomarkers in Parkinson’s Disease
doi: 10.1007/s13311-023-01379-z
Figure Lengend Snippet: Selected studies in aSyn-SAA and skin immunofluorescence/immunohistochemistry
Article Snippet: Kuzkina et al. [ ] ,
Techniques: Immunofluorescence, Biomarker Discovery
Journal: Neurotherapeutics
Article Title: Fluid and Biopsy Based Biomarkers in Parkinson’s Disease
doi: 10.1007/s13311-023-01379-z
Figure Lengend Snippet: aSyn-SAA metrics. Tissue or fluid samples are analyzed with fluorescence measurements read at given intervals which can be used to establish curves shown in ( a ). From these curves, a variety of metrics can be derived including maximum fluorescence, time to threshold (or time lag), time to 50% of maximum fluorescence (T50) or area under the curve calculations; however, these metrics have not consistently been shown to relate to clinical characteristics or pathological burden within PD patients. If a sample undergoes serial dilution and is analyzed at these different dilutions as shown in ( b ), the dilution at which 50% of well remain positive can be used to estimate the SD50 which may have more relevance to disease activity in some studies. In this example the estimated -log(SD50) = 7. Created with Biorender.com
Article Snippet: Kuzkina et al. [ ] ,
Techniques: Fluorescence, Derivative Assay, Serial Dilution, Activity Assay
Journal: Neurotherapeutics
Article Title: Fluid and Biopsy Based Biomarkers in Parkinson’s Disease
doi: 10.1007/s13311-023-01379-z
Figure Lengend Snippet: aSyn assays from biofluids and tissue. Summary of static aSyn assessments, peripheral tissue immunohistochemistry, immunofluorescence and aSyn-SAA assays in different tissues and fluids studied currently with spinal fluid aSyn-SAA and skin aSyn-SAA and immunofluorescence assays showing the greatest accuracy to date but with many other assays still in development. Created with Biorender.com
Article Snippet: Kuzkina et al. [ ] ,
Techniques: Immunohistochemistry, Immunofluorescence
Journal: International Journal of Molecular Sciences
Article Title: Seeding Aggregation Assays in Lewy Bodies Disorders: A Narrative State-of-the-Art Review
doi: 10.3390/ijms251910783
Figure Lengend Snippet: Studies on α-syn-SAAs using CSF and BH samples.
Article Snippet: Brockmann et al., 2021 [ ] , RT-QuIC , CSF , NO , sporadic PD PD GBA PD LRRK2 PD recessive * 3 sporadic DLB DLB GBA NMCs * 4 , 107/26 99/26 9/26 20/26 33/26 16/26 14/26 , According to
Techniques: Control, Phospho-proteomics, Diagnostic Assay, Activity Assay, Sonication, Biomarker Discovery, Fluorescence
Journal: Annals of Clinical and Translational Neurology
Article Title: Alpha‐synuclein RT ‐ QuIC assay in gastroduodenal and skin biopsies of Parkinson disease patients
doi: 10.1002/acn3.52282
Figure Lengend Snippet: Demographic, clinical, and biomarker data in patients and controls.
Article Snippet: These methodologies, named seed amplification assays (SAA), exploit the seeding potential of misfolded αSyn in biofluid or peripheral tissues, including cerebrospinal fluid (CSF), skin, olfactory and gastro‐intestinal mucosa, and potentially serum., , , , , , , Robust SAA data have been obtained using both CSF and skin, demonstrating high specificity (>90%) and sensitivity of 85–100% in PD and Dementia with Lewy Bodies (DLB) , , , , , and 75–90% in isolated REM‐Behavior Disorder (IRBD)., , However, our understanding of the accuracy of αSyn SAA when applied to other accessible tissues and
Techniques: Biomarker Discovery
Journal: Frontiers in Molecular Biosciences
Article Title: New protocol for kinetic assay seeding ability recovery “KASAR” from formalin-fixed paraffin-embedded tissues
doi: 10.3389/fmolb.2023.1087982
Figure Lengend Snippet: Fresh frozen versus formalin-fixed brain tissue in RT-QuIC. (A) The overall mean fluorescence of fresh DLB positive brain homogenate (green) vs. formalin-fixed DLB positive brain homogenate (orange) and controls (teal and violet) as a percentage of the peak fluorescence (% Max) reading. The shaded areas indicate the standard deviation of the readings over time. The black dotted line indicates the calculated aggregation threshold above which indicates positive (n = 4) (fluoresces strongly) whereas failing to cross the threshold indicates negative (n = 3) readings. (B) % Max RFU of the mean of each sample. Results were analyzed using t-test. Data expressed as the mean of three technical replicates. ** = p < 0.01 and not significant (ns) when p > 0.05.
Article Snippet: Each reaction consisted of 2 µl of test sample as seed and 98 µl of
Techniques: Fluorescence, Standard Deviation
Journal: Frontiers in Molecular Biosciences
Article Title: New protocol for kinetic assay seeding ability recovery “KASAR” from formalin-fixed paraffin-embedded tissues
doi: 10.3389/fmolb.2023.1087982
Figure Lengend Snippet: RT-QuIC results for fresh frozen, FFPE Core, and KASAR-treated FFPE core brain tissues. (A) Mean amplification curves of four individual fresh frozen samples of DLB (green with open circles) and three control (purple with black triangles) brain homogenates run in triplicate, the same DLB (orange with x’s) and control (blue with open triangles) brains after processing and being embedded into wax blocks, and the same DLB (magenta) and control (gray) brains again after KASAR treatment. The graphs of all KASAR-processed samples are nearly indistinguishable from the fresh frozen results. (B) Quantitative analysis of the mean % Max RFU showing that the seeding activity of KASAR-treated FFPE “core” samples was nearly fully recovered relative to fresh frozen samples. Two out of four FFPE DLB samples were false negatives and failed to cross the aggregation threshold determined by fluorescence greater than 10% Max RFU. The other two FFPE DLB samples did cross the threshold but have a reduced % Max RFU compared to fresh and KASAR-treated FFPE samples. Results were analyzed using t-test. Data expressed as the mean of three technical replicates. Ns, not significant.
Article Snippet: Each reaction consisted of 2 µl of test sample as seed and 98 µl of
Techniques: Amplification, Activity Assay, Fluorescence
Journal: Frontiers in Molecular Biosciences
Article Title: New protocol for kinetic assay seeding ability recovery “KASAR” from formalin-fixed paraffin-embedded tissues
doi: 10.3389/fmolb.2023.1087982
Figure Lengend Snippet: KASAR-treated FFPE SMG slide-mounted samples demonstrate repeatability across runs. (A) Simple linear regression of % Max RFU of (n = 28) samples run via RT-QuIC between two different plates, using an unblinded run as the predictor of another run with samples blinded. (B) Receiver operating characteristic (ROC) curve plotting the true-positive rate against the false-positive rate along with a determination of the area under the curve (AUC). All diagnoses were confirmed at the time of death (n = 28).
Article Snippet: Each reaction consisted of 2 µl of test sample as seed and 98 µl of
Techniques: